Dyslipidemia

Obese individuals were found to have a higher odds ratio of developing IIH compared to non-obese people.

A statement from Regeneron announced their ANGPTL3 inhibitor evinacumab (Evkeeza) received approval as an adjunct therapy for lowering LDL-C in patients 12 years and older with homozygous familial hypercholesterolemia.

The indication is the first granted to an ANGPTL3 inhibitor in the US.

Researchers believe identifying more risk factors could be beneficial in reducing cardiovascular disease.

Infants managed using real-time CGM spent longer time in the glucose concentration target range than those receiving standard of care.

More than 20% of TIA patients suffered a stroke within 7 days following the baseline attack.

Low-density lipoprotein cholesterol level was lower by approximately 19 mg per deciliter and systolic blood pressure was lower by approximately 5.8 mm Hg with the polypill and with combination therapy than with placebo.

High adolescent non–HDL-C levels were strongly associated with the presence of coronary artery calcification in mid-adulthood.

The clinical presentation of influenza myocarditis includes, fever, myalgia, palpitations, shortness of breath, and chest pains.

The guidelines list more than 40 recommendations related to blood pressure targets, screening and diagnosis, and overall cardiovascular disease risk management strategies.

The association between genetic liability to smoking and ASCVD was independent from the effects of smoking on traditional cardiovascular risk factors.

A lipidologist from Connecticut describes his experience during the COVID-19 pandemic and explains why he sees getting the vaccine as his "biggest contribution" to healthcare during the pandemic.

Patients who continue RAS therapy had a lower risk of kidney replacement therapy.

This article features the top 6 stories in Practical Cardiology's coverage of lipid management in 2020.

Practical Cardiology Advisory Board Member Brett Nowlan, MD, offers his perspective on the most important advances and topics in the field of lipidology from 2020.

The US FDA has declined to approve inclisiran ahead of its PDUFA date of December 23, instead issuing a CRL citing unresolved facility inspection issues.

Novartis indicates they will address manufacturing issues cited by the FDA.

Learn more about the importance of educating patients on the differences between store-bought fish oil supplements and therapies derived from omega-3 such as icosapent ethyl (Vascepa).

Despite these findings, there is still uncertainty as to whether mitigating symptoms of depression can lower cardiovascular risk.

There is concern over whether or not patients are adhering to their treatment during the pandemic.

Dr. Gerald Shulman discusses how diabetes can eventually be reversed.

By addressing insulin resistance, researchers believe they can reduce the comorbidities associated with type 2 diabetes.

Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes.

Diabetic patients are more susceptible to severe COVID-19 outcomes.

Dr. Kausik Ray presents new data on inclisiran and bempedoic acid as cholesterol lowering medications.